Literature DB >> 21658646

Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report.

T Pressler1, C Bohmova, S Conway, S Dumcius, L Hjelte, N Høiby, H Kollberg, B Tümmler, V Vavrova.   

Abstract

Chronic pulmonary infection with P. aeruginosa develops in most patients with cystic fibrosis (CF); by adulthood 80% of patients are infected and chronic P. aeruginosa infection is the primary cause of increased morbidity and mortality in CF. Chronic infection is preceded by an intermittent stage of infection. The initial stage is characteristically followed by the gradual emergence of mucoid variants of the colonizing strains and a rise in anti-Pseudomonas antibodies. In addition to optimizing existing therapeutic strategies, effective new agents need to be identified. Studies in patients with CF are particularly challenging: the progressive nature of the disease and the wide variation in severity influence considerably the outcome of drug testing. A validated, universally accepted, and clinically useful classification of patients infected with P. aeruginosa, particularly those chronically infected, is needed that can be used as both a criterion for patient selection for clinical trials and as a study endpoint.
Copyright © 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21658646     DOI: 10.1016/S1569-1993(11)60011-8

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  43 in total

1.  Benign outcome among positive cystic fibrosis newborn screen children with non-CF-causing variants.

Authors:  Danieli Barino Salinas; Patrick R Sosnay; Colleen Azen; Suzanne Young; Karen S Raraigh; Thomas G Keens; Martin Kharrazi
Journal:  J Cyst Fibros       Date:  2015-03-29       Impact factor: 5.482

2.  Pseudomonas infection in antibody deficient patients.

Authors:  Sai S Duraisingham; Steven Hanson; Matthew Buckland; Sofia Grigoriadou; Hilary J Longhurst
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2014-12-16

3.  First report of chronic pulmonary infection by KPC-3-producing and colistin-resistant Klebsiella pneumoniae sequence type 258 (ST258) in an adult patient with cystic fibrosis.

Authors:  Emanuele Delfino; Daniele Roberto Giacobbe; Valerio Del Bono; Erika Coppo; Anna Marchese; Graziana Manno; Patrizia Morelli; Laura Minicucci; Claudio Viscoli
Journal:  J Clin Microbiol       Date:  2015-02-04       Impact factor: 5.948

4.  Cystic fibrosis in Austria.

Authors:  Thomas Frischer; Ernst Eber; Helmut Ellemunter; Angela Zacharasiewicz; Ingrid Kaluza; Josef Riedler; Sabine Renner
Journal:  Wien Klin Wochenschr       Date:  2017-02-24       Impact factor: 1.704

5.  Pseudomonas aeruginosa stimulates nuclear sphingosine-1-phosphate generation and epigenetic regulation of lung inflammatory injury.

Authors:  Viswanathan Natarajan; Panfeng Fu; David L Ebenezer; Evgeny V Berdyshev; Irina A Bronova; Yuru Liu; Chinnaswamy Tiruppathi; Yulia Komarova; Elizaveta V Benevolenskaya; Vidyani Suryadevara; Alison W Ha; Anantha Harijith; Rubin M Tuder
Journal:  Thorax       Date:  2019-02-05       Impact factor: 9.139

Review 6.  Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin.

Authors:  Zarmina Ehsan; John P Clancy
Journal:  Future Microbiol       Date:  2015-11-17       Impact factor: 3.165

7.  Phenotypes of California CF Newborn Screen-Positive Children with CFTR 5T Allele by TG Repeat Length.

Authors:  Danieli Barino Salinas; Colleen Azen; Suzanne Young; Thomas G Keens; Martin Kharrazi; Richard B Parad
Journal:  Genet Test Mol Biomarkers       Date:  2016-07-22

8.  Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis.

Authors:  S L Heltshe; U Khan; V Beckett; A Baines; J Emerson; D B Sanders; R L Gibson; W Morgan; M Rosenfeld
Journal:  J Cyst Fibros       Date:  2017-10-28       Impact factor: 5.482

9.  "Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis.

Authors:  Peter H Gilligan; Damian G Downey; J Stuart Elborn; Patrick A Flume; Sebastian Funk; Deirdre Gilpin; Timothy J Kidd; John McCaughan; B Cherie Millar; Philip G Murphy; Jacqueline C Rendall; Michael M Tunney; John E Moore
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

10.  Exercise oxidative skeletal muscle metabolism in adolescents with cystic fibrosis.

Authors:  Maarten Werkman; Jeroen Jeneson; Paul Helders; Bert Arets; Kors van der Ent; Birgitta Velthuis; Rutger Nievelstein; Tim Takken; Erik Hulzebos
Journal:  Exp Physiol       Date:  2016-03       Impact factor: 2.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.